The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global bioburden testing market exhibited strong growth during 2015-2020. Bioburden testing assists in measuring the total viable count of microbial contamination in a product. It is widely used in the pharmaceutical industry to understand the different types and amounts of microorganisms in sterile medical devices throughout the production process. Prior to the test, a suitability experiment is usually conducted to ensure the effectiveness of the testing method while recovering the microorganisms present on the device.
At present, the governing authorities of numerous countries are implementing stringent regulatory norms to validate the sterilization process of medical devices. This represents one of the leading factors escalating the demand for bioburden testing to meet microbial quality and sterilization requirements of medical devices. Moreover, bioburden testing can be performed on devices as a part of the routine quality control process. Apart from this, major pharmaceutical manufacturers are focusing on producing safe products and achieving sterility assurance. This, in confluence with the rising utilization of single-use medical items, is influencing the market positively. Furthermore, as bioburden testing is an integral part of the microbiological monitoring program while manufacturing sterile products, it is gaining recognition in the cosmetics industry for maintaining the overall safety and performance of the packaged goods. Additionally, the surge in coronavirus disease (COVID-19) cases is escalating the need for bioburden reduction systems that utilize dry heat to support the reuse of particulate filtering facepiece respirators (FFRs). This, along with the growing food safety standards, is anticipated to drive the market further. Looking forward, IMARC Group expects the global bioburden testing market to grow at a CAGR of around 12% during the forecast period (2021-2026).
IMARC Group provides an analysis of the key trends in each sub-segment of the global bioburden testing market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, product, test type, application and end user.
Breakup by Product:
Breakup by Test Type:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Becton Dickinson and Company, Biomérieux SA (Compagnie Merieux Alliance), Charles River Laboratories Inc, Merck KGaA, Nelson Laboratories LLC (Sotera Health LLC), North American Science Associates Inc., Pacific BioLabs Inc., SGS SA, Thermo Fisher Scientific Inc and Wuxi Apptec.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at